TNFRSF8 and angioimmunoblastic T-cell lymphoma: Recently, brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone therapy was found to provide a superior overall survival (OS) rate versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy as an initial treatment in both CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) [2,3].